|
|
News Breaks | | | | February 26, 2013 | | 16:03 EDT |  | KBIO | KaloBios presents clinical results from KB002 Phase 1/2 study
KaloBios Pharmaceuticals presented data from its Phase 1/2 study in persistent asthma for KB002, precursor chimeric anti-GM-CSF monoclonal antibody to KB003, at the American Academy of Allergy, Asthma & Immunology Annual Meeting in Austin, Texas. The findings demonstrated preliminary safety, tolerability, and signs of activity of anti- GM-CSF antibodies in asthma and support continued development of the company's Humaneered KB003 anti-GM-CSF monoclonal antibody in severe asthma. KB003 is currently in a Phase 2 trial in severe asthma patients inadequately controlled by corticosteroids. "These initial clinical results with KB002 in asthma are highly encouraging. KB002 was well-tolerated, with no significant adverse events in the study population. When KB002 was added to patients' standard of care treatment, the study also showed a reduction in airway inflammation and improvements in FEV1. Moreover, asthmatics with reversible FEV1 at baseline showed greater FEV1 responses than non-reversible patients. As a result, we are targeting this patient population in our ongoing Phase 2 KB003 study," said chief medical officer Nestor Molfino. | |
|
News For KBIO From The Last 14 Days Check below for free stories on KBIO the last two weeks. |
|
|
| May 14, 2013 | | 16:03 EDT |  | KBIO | KaloBios reports Q1 EPS (55c), consensus (45c)
 Subscribe for More Information | | | May 10, 2013 | | 07:24 EDT |  | KBIO | Credit Suisse to host a conference
Subscribe for More Information | |
|
|
|
|
|
|
